Background: During surveillance colonoscopy of patients with long-standing ulcerative colitis [UC], a variety of dysplastic and non-dysplastic lesions are detected. The aim of this study was to address the diagnostic accuracy of endoscopic characterization of endoscopic trimodal imaging [ETMI] and chromoendoscopy [CE]. ETMI includes the combination of autofluorescence imaging [AFI], narrow band imaging [NBI] and white light endoscopy [WLE]. Methods: This is a pre-specified additional analysis of a multi-centre, randomized controlled trial that compared AFI with CE for dysplasia detection in 210 patients with long-standing UC [FIND-UC trial]. In the AFI arm, endoscopists used the ETMI system to record AFI colour, Kudo pit pattern using NBI and WLE for lesion characterization. For AFI, purple colour and ambiguous colour combined with pit pattern type III-V on NBI was considered dysplastic. Kudo pit pattern was described in the CE arm. For pit pattern description using NBI and CE, type III-V was considered dysplastic. Histology was the reference standard. Results: In total, 52 dysplastic and 255 non-dysplastic lesions were detected. Overall sensitivity for real-time prediction of dysplasia was 76.9% (95% confidence interval [CI] 
Introduction
Patients with long-standing ulcerative colitis [UC] are at increased risk for developing colorectal cancer [CRC] . 1, 2 As it is believed that CRC in patients with long-standing UC develops gradually from chronically inflamed mucosa to dysplasia to CRC, surveillance colonoscopies are recommended to detect dysplasia in a timely manner. 3 Colonoscopic surveillance reduces CRC incidence and mortality, in part due to early detection of dysplasia. 4 Chromoendoscopy [CE], which uses application of topical dye on the mucosa to highlight subtle differences, with targeted biopsies of visible lesions, is currently recommended as surveillance strategy as it has consistently been shown to increase dysplasia detection rates. [5] [6] [7] However, apart from detecting dysplastic lesions, a variety of non-dysplastic lesions is detected during surveillance. These non-dysplastic lesions comprise post-inflammatory polyps, lesions caused by ongoing chronic active inflammation or scarring, and the more common hyperplastic lesions.
It is important to differentiate between dysplastic and nondysplastic lesions endoscopically as only dysplastic lesions need to be removed to prevent CRC development. 8 In an ideal situation, endoscopic determination as to whether a lesion is dysplastic or not should have a high sensitivity combined with a high negative predictive value for predicting dysplastic histology. This would imply that all dysplastic lesions are identified by endoscopic diagnosis and that lesions confidently characterized as non-dysplastic can be left in situ without biopsy or resection. Several endoscopic imaging techniques have been studied regarding their ability to differentiate dysplastic from non-dysplastic mucosa in patients with long-standing colitis. Besides CE, [9] [10] [11] [12] [13] these include advanced imaging techniques such as i-Scan, 11 autofluorescence imaging [AFI], 14 narrow band imaging [NBI] 9,14-16 and confocal laser endomicroscopy [CLE] . 17, 18 Endoscopic trimodal imaging [ETMI] incorporates AFI, NBI and high-definition white-light endoscopy [WLE] into one endoscopy system. The aim of the current study was to assess ETMI and CE for their accuracy to characterize dysplastic and non-dysplastic lesions in patients with long-standing UC.
Methods

Study design
This study was a pre-specified additional analysis of the FIND-UC trial ['an international multi-center, randomized controlled trial of chromoendoscopy versus autoFluorescence Imaging for Neoplasia Detection in patients with long-standing Ulcerative Colitis']. Methods and outcomes of this trial are described in detail elsewhere. 19 The FIND-UC trial was a randomized controlled parallel trial in which dysplasia detection rates of AFI and CE were compared to determine whether AFI should be further investigated as a dysplasia surveillance method in patients with long-standing UC [Netherlands Trial Register number 4062]. In this study, AFI did not meet criteria for proceeding to a large inferiority trial and existing AFI technology should therefore not be further investigated as an alternative dysplasia detection surveillance method. In the FIND-UC study, AFI was part of an ETMI system which incorporates AFI, NBI and WLE. This pre-specified additional analysis focuses on the accuracy of ETMI and CE to characterize dysplastic and non-dysplastic lesions. The Standards for Reporting of Diagnostic Accuracy [STARD] guideline was followed in reporting the diagnostic test accuracies of all modalities with respect to lesion differentiation. 20 
Patients
Patients with long-standing UC scheduled for dysplasia surveillance at one of five participating centres in the UK and the Netherlands were consecutively approached for participation in the FIND-UC trial. Patients were eligible for inclusion in this trial if they were 18 years and older and had long-standing UC, which was defined as left-sided colitis [Montreal E2] of at least 15 years or pancolitis [Montreal E3] of at least 8 years. 21 Patients were excluded prior to colonoscopy if they were unable to provide informed consent, had noticed a change of bowel habit in the 2 months prior to the surveillance colonoscopy, were referred for evaluation of an earlier detected lesion [or refused surgery], were unfit to undergo surveillance colonoscopy, had a proven genetic predisposition for CRC development, used anticoagulant drugs or had a coagulation disorder which precluded taking biopsies. Prior to randomizing during the study procedure, discontinuation criteria included a Boston Bowel Preparation Scale 22 <6 and/or active colitis 23 assessed during intubation. Active colitis was defined as a Mayo endoscopic subscore >1 in the proximal [caecum and ascending], transverse or distal [descending, sigmoid and rectum] colon. 23 
Endoscopists and endoscopic equipment
At each participating centre, two endoscopists participated in the study. At the start of the study, all endoscopists were required to have performed at least 20 colonoscopies with the endoscopic equipment in patients with long-standing UC. All participating endoscopists attended a 1-day clinical teaching session, in which ETMI and CE were discussed in detail and a hands-on colonoscopy was performed. The training also included a presentation of multiple dysplastic and non-dysplastic lesions detected by ETMI or CE in patients with long-standing UC.
Colonoscopies were performed using the Lucera Elite video processor system with sequential red-green-blue illumination [CV-H260; Olympus Medical Systems Co.] and CFH240AZL/I colonoscopes [Olympus Medical Systems Co.] . Switching between the three different imaging modes [AFI, NBI and high-definition WLE] in the ETMI system was performed by pressing a button on the shaft of the colonoscope. High-definition monitor output was used for both arms placed at appropriate viewing distances at the discretion of the endoscopist.
Study procedure
Patients in the FIND-UC study were randomized upon reaching the caecum to determine whether AFI or CE was used during extubation for lesion detection. Minimization was performed during randomization for previous dysplasia and concomitant primary sclerosing cholangitis, known risk factors for developing dysplasia, to provide a better balance between each randomization group. When patients were randomized for AFI, the imaging mode was switched to AFI. When randomized to CE, segmental pancolonic spraying of 0.1% methylene blue or 0.3% indigo carmine was performed before inspection with WLE. 24 During withdrawal from the caecum or terminal ileum, the colon was scrutinized for the presence of lesions, mucosal irregularities, ulcers and strictures. If a lesion was detected, the segment of the colon was registered, the size was estimated by using a reference of known diameter [e.g. open biopsy forceps] and the morphology of the lesion was described according to the Paris classification. 25 Subsequently, all detected lesions and their adjacent mucosa were sampled for histopathological evaluation. Whether a lesion was biopsied only or removed completely was made at the discretion of the endoscopist performing the study procedure.
Real-time lesion characterization [index test]
When patients were randomized for AFI, detected lesions were evaluated using the ETMI system. When a lesion was detected with AFI, the colour of the lesion was recorded [purple, ambiguous, green]. Thereafter, the imaging mode was switched to NBI to record the Kudo pit pattern [type I-V]. 26 Last, the imaging mode was switched to WLE to evaluate the lesion. Per detected lesion, endoscopists were asked on which imaging mode they based their endoscopic diagnosis [AFI, NBI or WLE] and the endoscopic diagnosis of that imaging method was chosen to determine the accuracy of endoscopic characterization for ETMI. For AFI, purple was considered dysplastic, while green was considered non-dysplastic. Lesions of ambiguous colour on AFI and Kudo pit pattern type I-II on NBI were also considered non-dysplastic, while those with Kudo pit pattern type III-V were considered dysplastic. For endoscopic characterization with Kudo pit pattern using NBI, Kudo pit pattern type III-V was considered dysplastic. Where there was a discrepancy between AFI colour and Kudo pit pattern [i.e. AFI colour green and Kudo III-V or AFI colour purple and Kudo I-II], the decision whether the lesion was endoscopically considered dysplastic or non-dysplastic was therefore made at the discretion of the endoscopist. For WLE, the decision whether a lesion was considered dysplastic or non-dysplastic was made at the discretion of the endoscopist performing the study procedure. Per evaluated lesion, confidence levels [high or low] for the endoscopic diagnosis were recorded.
When patients were randomized to CE during extubation and when a lesion was detected, the Kudo pit pattern [type I-V] classification was used to classify the lesion. For endoscopic characterization with Kudo pit pattern using CE, Kudo pit pattern type III-V was considered dysplastic and Kudo pit pattern type I-II was considered non-dysplastic. For all lesions, the endoscopist recorded a level of confidence for the endoscopic diagnosis.
In both study arms, when patients were diagnosed with more than three post-inflammatory or hyperplastic appearing polyps, biopsies were taken for a maximum of three of these lesions per patient. Only those post-inflammatory or hyperplastic polyps with an aberrant aspect on AFI, NBI, WLE or CE were biopsied if more than three post-inflammatory or hyperplastic appearing polyps were biopsied. In the protocol, no endoscopic criteria were stated for post-inflammatory or hyperplastic appearing polyps, nor for an aberrant aspect on AFI, NBI, WLE or CE and this decision was made at the discretion of the endoscopist performing the study-procedure.
Histopathology [reference test]
All lesions were collected in separate histology containers. Initial histological assessment was performed by pathologists with expertise in gastrointestinal pathology in each centre, who were blinded to the endoscopic assessments. All dysplastic cases were centrally reviewed by a second specialist pathologist in the UK and the Netherlands to confirm initial findings. To further strengthen initial histopathology results, a random 10% of all histological samples were centrally reviewed by a specialist pathologist blinded to the initial diagnosis. Initial histological assessment and histology review was performed according to the revised Vienna guidelines. 27 Sessile serrated lesions [SSLs] were defined as serrated lesions with at least two adjacent or three irregularly distributed, dilated or horizontally branched crypts with an 'L' or inverted 'T'. 28 Histopathological outcomes of dysplasia were considered the reference standard. Dysplastic histology was defined as cancer, adenomas and SSLs diagnosed with dysplasia, and other histology specimens containing dysplasia. Histopathology outcomes indefinite for dysplasia and SSLs without dysplasia were considered non-dysplastic. 
Study outcomes
The primary outcome of this study was the diagnostic test accuracy [e.g. sensitivity, specificity, positive and negative predictive values] of ETMI and CE for the endoscopic characterization of dysplastic lesions in patients with long-standing UC. Secondary outcomes included a description of detected dysplastic and non-dysplastic lesions; identification of endoscopic factors associated with dysplastic lesions; and a description of endoscopic differentiation of SSLs. 
Statistical analysis
Results
Between August 1, 2013 and March 10, 2017, 105 patients were randomized for inspection with AFI and 105 with CE. Baseline characteristics of these patients are shown in Table 1 . In total, 312 lesions were detected in the 210 patients included in this trial [ Figure 1 ]. Of 312 detected lesions, 52 [16.7%] 
Lesion characteristics
Clinicopathological features of detected lesions are shown in Table 3 
Endoscopic characterization of SSLs
Of 18 detected SSLs, most were located proximal to the descending colon [78%] and flat-elevated or flat [Paris IIa or IIb] morphology was seen in 83% of SSLs. Using AFI during extubation, four SSLs were detected. Two of these were endoscopically diagnosed as postinflammatory polyps. AFI colour was described as purple [50%] or green [50%]. Using NBI for Kudo pit pattern description, types II and III [for the two expected post-inflammatory polyps] were described. All were confidently predicted to be non-dysplastic. Using CE for inspection, 14 SSLs were detected. Type II pit pattern was described in 100% of SSLs detected with CE.
Discussion
In this study, part of a parallel prospective randomized trial which compared AFI and CE for dysplasia detection in 210 patients with long-standing UC, we assessed real-time lesion characterization using ETMI and CE. Using the ETMI system, lesions were characterized based on AFI colour, Kudo overall ETMI results. Possibly, AFI colour is the most reliable characterization technique and may be easier to interpret than Kudo pit pattern using NBI or CE. In a previous study by van den Broek et al., lesion characterization using AFI and NBI was recorded.
14 In this study, sensitivity for AFI, NBI and the two modalities combined was 100%, 75% and 100%, respectively. Negative predictive value for real-time dysplasia prediction was only reported for evaluation of Kudo pit pattern using NBI and was 94%. Non-magnifying NBI for real-time prediction of dysplasia has been assessed in two other studies; sensitivity for dysplasia using NBI for Kudo pit pattern analysis was 42% and 76%, respectively. 15, 29 Negative predictive values were 88% and 95%, respectively. Non-magnifying CE has also been studied for real-time dysplasia prediction; sensitivities and negative predictive values are in the range 32-93% and 88-98% respectively. 10, 11, 30 All these values correspond to the sensitivities and negative predictive values for real-time dysplasia predictions using different imaging techniques that we report in the current study.
In a recently published image analysis study, NBI and CE were compared for differentiation between dysplastic and non-dysplastic lesions using the Kudo pit pattern, assessed by ten specialist endoscopists. 9 Sensitivity for CE for Kudo pit pattern diagnosis of dysplasia was significantly higher compared to NBI [88% vs 60%, p < 0.01]. The negative predictive values for Kudo pit pattern analysis of both techniques were similar [89% vs 89%, p = 0.74]. Inter-observer agreement was higher for diagnosis of dysplasia using NBI than with CE. However, the overall agreement between specialist endoscopists was only moderate to substantial for differentiating dysplastic from non-dysplastic lesions, indicating low inter-observer agreement, which has been corroborated in another image-based study. 31 Lastly, CLE, which has been exclusively investigated in academic centres, is an imaging technique that provides magnified images of gastrointestinal epithelium comparable to histopathology. Although promising, reported diagnostic accuracies are variable between studies and CLE should therefore be considered as a complementary tool to histopathology instead of a replacement of histopathology. 17, 18 The results of all these studies show that there is considerable disagreement in lesion characterization of dysplasia by specialist endoscopists. Furthermore, there seems to be no preferred imaging technique for differentiating dysplastic from non-dysplastic lesions in patients with long-standing UC. This emphasizes the value of pathological assessment of all potentially dysplastic lesions.
Several other endoscopic features seem to be associated with a lesion being dysplastic in patients with long-standing UC. In this study we showed that proximal location and non-polypoid morphology [Paris IIa, IIb and IIc] were associated with dysplasia. Carballal et al. showed similar findings in a large prospective cohort study of 1000 patients with long-standing UC, in that proximally located lesions were also more likely to be dysplastic. 10 Contrary to our findings, these authors showed that lesions with a polypoid morphology [Paris Ip, Isp and Is] were associated with dysplastic histology. A possible explanation for this difference could be the Abbreviations: AFI = autofluorescence imaging, CE = chromoendoscopy, CRC = colorectal cancer, HGD = high-grade dysplasia, LGD = low-grade dysplasia, SSL = sessile serrated lesion, ID = indefinite for dysplasia.
a For one lesion, no location was recorded. b Includes hepatic and splenic flexure. suboptimal inter-observer agreement in describing polyp morphology using the Paris classification. 32 Altogether, these endoscopic features can contribute to dysplasia differentiation in patients with long-standing UC and could be considered alongside the Kudo pit pattern classification.
In the average-risk population, the serrated neoplasia pathway has been increasingly acknowledged as an independent pathway to CRC development. 33 In this pathway, SSLs are considered the main precursor lesions. Previous studies reported that some CRCs may be attributed to the serrated neoplasia pathway in inflammatory bowel disease. [34] [35] [36] Moreover, patients with SSLs seem to have a higher risk of synchronous dysplasia and may be at increased risk of developing future visible dysplasia. 37, 38 Therefore, detecting SSLs at colonoscopy seems of importance. In the current study, AFI detected four SSLs; two of these were green on AFI and had Kudo type II pit pattern on NBI. Using CE, type II pit pattern was described in 100% of SSLs. As endoscopic recognition of SSLs based on Kudo pit pattern alone seems difficult, we suggest that all polyps proximal to the rectum and sigmoid that appear serrated are removed or biopsied, because these may be SSLs. However, given the scarce evidence of the serrated neoplasia pathway in patients with colitis, future studies should investigate to what extent the serrated pathway is involved in CRC development in inflammatory bowel disease. 39 The main limitation of our study is that all lesions assessed with ETMI were detected in the AFI arm of the FIND-UC study. Lesions were detected by AFI colour and therefore the performance of AFI is biased by selection as it was used as a detection technique rather than a characterization technique. Lesions detected with AFI therefore had a higher probability of being accurately characterized through AFI. Lesions detected with AFI were subsequently assessed with NBI and WLE as part of the ETMI system. It is therefore difficult to allocate the diagnostic accuracy to each individual technique as endoscopists were also influenced by the other techniques used at the same time. This also affects the diagnostic performance of NBI and WLE as stand-alone tests and these results may therefore also be biased. Although the Kudo pit pattern classification has been used in several studies for lesion characterization in patients with longstanding UC, it should be noted that the Kudo pit pattern classification is not specifically designed to be used in inflammatory bowel disease or with NBI. Furthermore, all lesions were assessed during endoscopy by specialist endoscopists with an interest in performing endoscopy research. This may have also caused selection bias, as it is unclear how less experienced endoscopists would have performed. However, based on previous literature we anticipate that if differentiation proves difficult amongst specialists, this can be extrapolated to endoscopists with less experience in optical diagnosis of lesions detected in patients with long-standing UC. In addition, the degree of confidence was subjective, but was associated with an increased accuracy of differentiating between dysplastic and non-dysplastic lesions. Last, the number of dysplastic lesions assessed per single endoscopist participating in our study was quite small. Only 14 were evaluated with ETMI and 38 with CE. Our study findings should therefore be confirmed in larger sample studies performed in daily clinical practice.
Even when using multiple advanced imaging techniques such as AFI, NBI, high-definition WLE or CE, specialist endoscopists cannot reliably identify dysplastic lesions encountered during surveillance in patients with long-standing UC. This emphasizes the value of pathological assessment of all potentially dysplastic lesions that are encountered during colonoscopy surveillance in patients with longstanding UC. The high negative predictive value of all techniques indicates that using these techniques may be very helpful in excluding dysplastic lesions. However, future studies should assess whether the results of lesion characterization by specialist endoscopists in this study can be extrapolated to general endoscopy practice.
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